Jan. 13, 2010
Sirnaomics Licenses Polypeptide Nanoparticle Technology for Its siRNA Therapeutic Product Development
GAITHERSBURG, MD -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has licensed a polypeptide nanoparticle technology invented by Professor A. James Mixson of University of Maryland Medical School. The licensing agreement grants Sirnaomics exclusive rights to a patent covering use of Histidine-Lysine polymer (HKP) for siRNA therapeutics in the areas of wound healing and ocular diseases (U.S. patent application 60/173,576 filed December 29, 1999). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to advancing RNA interference (RNAi) technology for novel targeted therapeutic development. The company's multi-targeted siRNA therapeutic programs utilizing its nanoparticle-enhanced delivery technologies represent a unique approach for truly realizing the advantages of small interfering RNA (siRNA)-based drugs to treat various critical human diseases.   (Read all...)

Dec 1, 2009
China Takes Aim At RNAi (cover news on GEN)
Sirnaomics Introduces Its RNAi Technologies at "RNAi Asia 2009"
China-based companies, others with facilities or collaborative ventures in China, and academic groups all committed to advancing RNA-interference (RNAi) research and therapeutic drug development were well-represented at Select Biosciences’ “RNAi Asia” meeting held recently in Kunshan, China. Most of the siRNA work going on in China is being funded by the government, with industry only playing a small role at present, according to Patrick Lu, Ph.D., president and CEO of Sirnaomics...  (Read all...)

July 22, 2009
Sirnaomics Receives SBIR Grant from NIH/NCI For Its Multi-Targeted Lung Cancer siRNA Therapeutics

Gaithersburg, Maryland (July 22, 2009, PR Newswire) - Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has received an SBIR (small business innovation research) grant from National Cancer Institute (NCI), National Institute of Health (NIH), for its novel siRNA therapeutics to treat lung cancer. Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to advancing RNA interference (RNAi) Technology for novel targeted therapeutic development. The company's multi-targeted siRNA therapeutic programs utilizing its nanoparticle-enhanced delivery technologies represent a unique approach for truly realizing the advantages of small interfering RNA (siRNA)-based drugs to treat various critical human diseases. Sirnaomics has successfully attracted grants from NIH and the State of Maryland. 
Read in detail...

March 22, 2009
Sirnaomics Aboard the "Same Boat" in Maryland
Executives Attend the Summit Between Suzhou Delegation and State of Maryland Government

“All in the Same Boat” is the theme of this Summit meeting hosted by Suzhou Municipal Government, Maryland's Office of the Secretary of State, Maryland Department of Business & Economic Development (DBED), Montgomery County Department of Economic Development, Maryland-China Business Council and Maryland Center China. This event, also known as a “Doing Business with China” forum, aims at enhancing the bilateral economic and trade relations, as well as business and talent exchanges and cooperation, was held in Hyatt Agency, Bethesda, Maryland, on March 20. The Suzhou delegation, headed by the city’s Secretary Mr. Wang Rong, received warm welcome by the state and county officials as well as some major companies from this area. Sirnaomics executives including Dr Patrick Lu, Dr Harry Yang and Mr George Ji also attended the conference.
(Read all...)

January 22, 2009
President & CEO Dr. Lu Presents at "Executing on the Promise of RNAi" Conference in Cambridge, MA
The captioned conference is being held on January 22-23 in Cambridge, MA. Dr. Patrick Lu is invited to give a case-study presentation about "Evaluating Market Potential Overseas" this afternoon, which will cover the topics of Development Cost Reduction, Access to Resources, and Market Potential for Growth.

Sirnaomics has set up a subsidiary entity in China in order to take advantage of the nation's low cost of labor and of preclinical and clinical study expenses, as well as the technical expertise of its research institutions. China, especially the Greater Shanghai area, is viewed as becoming the leading biomedical research and marketing center of Asia. The case study given by Dr. Lu explores the company's strategy for creating their business unit overseas for the development of RNAi therapeutics.

October 31, 2008
Dr. Patrick Lu and Team Receives Tech Pioneer Award by Suzhou Industrial Park
Suzhou Industrial Park today held an awarding event to congratulate a group of 19 Tech Pioneers for being awarded this Tech Pioneer Award. Dr. Patrick Lu, accompanied by his China executive team, stepped onto the stage to receive the award medal, plaque and certificate from the officials of Suzhou Industrial Park.

This is the second such award granted in Suzhou. The first award was given in 2007 to 22 of the technology pioneers in this industrial park. Over hundreds of individuals from the companies participated the competitive application process this year.   ()

October 28, 2008
Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
Sirnaomics, Inc. announced today that the company has received an SBIR (small business innovation research) grant from National Cancer Institute (NCI), National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to advancing RNA interference (RNAi) Technology for novel targeted therapeutic development. The company's multi-targeted siRNA therapeutic programs utilizing its nanoparticle-enhanced delivery technologies represent a unique approach for truly realizing the advantages of small interfering RNA (siRNA)-based drugs to treat various critical human diseases. Sirnaomics has successfully attracted grants and investments from the State of Maryland (Department of Business and Economics Development -- DBED), Maryland Industrial Partnerships (MIPS) and Montgomery County Technology Growth Programs (TGP), in addition to the State of Maryland Tax Credit Program for Biotechnology Investment.
(Read more...)

October 15, 2008
Montgomery County Executive's Delegation Cut Ribbon for Sirnaomics' China Subsidiary in Suzhou

A delegation led by Montgomery County Executive Mr. Isah Leggett is visiting China now, and is attending the opening ceremony of Suzhou Sirnaomics Pharmaceuticals Co. Ltd. today in the famous picturesque eastern city Suzhou. The newly opened local company is a subsidiary of the Montgomery-Maryland headquartered bio-tech company Sirnaomics, Inc., and is now settled down in BioBay of Suzhou Industrial Park.

The County Executive speaks highly of Sirnaomics and its founders for developing innovative RNAi technology and extending business and potential market to China.  Dr Patrick Lu, founder and President and CEO of Sianromics, along with co-founders Harry Yang, George Ji and other management team members are present at the ribbon-cutting event.

August 15, 2008
IBC Life Sciences to Organize the D2D Conference & Exhibition on Oct 20-22 in San Diego
IBC Life Sciences, a leading provider of conferences on microarray technologies, biomarkers and molecular diagnostics, has developed the Discovery2Diagnostics Conference & Exhibition (D2D) to reflect recent changes in these industries and to capture opportunities presented by the fast-paced developments in technologies and research throughout the discovery to diagnostics spectrum. The conference is also a combination of the 15th Annual Chips to Hits®, 7th Annual Biomarkers, and 7th annual Molecular Diagnostics meetings. The scope of this meeting will expand to including more RNAi related research and development as it affects sequencing and detection technologies, biomarkers and molecular diagnostics, recent work to deliver point-of-care (or near POC) molecular diagnostics and sessions with panel discussions on related regulatory and reimbursement issues. The challenges experienced by those involved in the Discovery2Diagnostics spectrum and the enabling breakthroughs that bridge the gap between biomarkers and molecular diagnostics in the R&D setting and the clinic will also be explored.

August 1, 2008
Sirnaomics Starts Setting Up Chinese Unit, Aims for Up to Three Clinical Trials in 2009
[RNAi News - July 31, 2008] Sirnaomics has begun setting up a corporate entity in China in order to take advantage of the nation’s low-cost labor and research materials, as well as the technical expertise of its research institutions, RNAi News has learned.

Sirnaomics President and CEO Patrick Lu said he views China, especially the Shanghai area where the business unit is located, as becoming “the leading biomedical research and marketing center of Asia. We want to have a foothold [there] … and build an entity as the leader in Asia for siRNA therapeutics.”

At the same time, Gaithersburg, Md.-based Sirnaomics is pushing forward its lead drugdevelopment program, a multi-siRNA cocktail for ocular diseases characterized by subfoveal choroidal neovascularization called STP-601, which it expects to enter a phase I trial in the first quarter of 2009. The company had previously been planning to launch the study before the end of this year (see RNAi News, 3/13/2008).  
More...>>

July 10, 2008
Sirnaomics Presents Its Technology at NIAID/NIH
Dr. Patrick Lu, President and CEO of Sirnaomics, Inc., and Dr. David Evans, Vice President for Discovery Research, have presented Sirnaomics’ technology platforms for fast development of anti-viral siRNA therapeutics against newly emerging viral pathogens to NIAID of NIH. The presentation was well received and resulted in multiple collaboration requests. This effort is to demonstrate the capability of Sirnaomics technology in bio-defense related applications.

June 26, 2008
Dr. Lu’s Presents at AAPS National Biotechnology Conference
Dr. Patrick Lu, President and CEO of Sirnaomics Inc., was invited to speak in the 2008 AAPS National Biotechnology Conference which took place on June 22-25, 2008 at the Metro Toronto Convention Centre in Toronto, Ontario Canada. In the session of “Effective Targeted Delivery of RNAi Diagnostics and Therapy”, Dr. Lu presented the work on “siRNA in Prophylactic and Therapeutic Regimens against SARS Coronavirus”, published two years ago in Nature Medicine, followed by the latest development of siRNA therapeutics to treat and protect the H5N1 infected mice. Using a novel nanoparticle-based delivery system with siRNA duplexes, the therapeutics benefits were significantly better than several other small molecule antiviral drugs. In a different roundtable discussion session: Challenges and Opportunities in SiRNA Delivery, Dr. Lu addressed specifically the issues regarding siRNA in vivo delivery, using nanoparticle-based siRNA packaging systems as examples. In response to the questions regarding the recent Nature paper (Ambati et al, March 26, 2008), Dr. Lu emphasized that the finding further revealed the importance of delivery for successful siRNA therapeutics.

May 29, 2008
CBA's 13th Annual Conference Opens in Shanghai Together with the 10th Shanghai Bio-Forum

The Chinese Biopharmaceutical Association (CBA; www.cba-usa.org) and Shanghai Bio-Forum (www.bio-forum.com) jointly held their annual conferences on “Global Biotech and Pharmaceutical Innovation and Development” at Shanghai International Convention Center in Shanghai, China, from May 28-30, 2008. This event provides an important forum for the Sino-American scientific and business communities to exchange ideas, foster collaboration, and extend network. Sirnaomics CEO Dr. Patrick Lu, Vice President Dr. David Evans, Vice President Dr. Harry Yang, and other executives and scientists have been speaking at various sessions during this conference.

More News...

April 22, 2008 - Tuesday
CEO Gives Keynote Speech at the 1st RNAi National Conference in China

March 13, 2008 - Friday
Sirnaomics Inks RNAi Drug Deal with GRL, May Run Ocular Disease Drug Trial in US

March 12, 2008 - Thursday
Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products

December 26, 2007 - Wednesday
Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs

October 12, 2007
Washington Business Journal: Scientist Launches New Venture with Same Technology

October 6, 2007 - Saturday
President & CEO Patrick Lu Presents at 3rd Annual Meeting of the Oligonucleotide Therapeutics Society in Berlin

September 20, 2007 - Thursday
RNAi News: Startup Sirnaomics Takes Aim at Phase I in China in 2008 Even As It Looks to Raise Cash

September 20, 2007 - Thursday
Dr. Lu Presents at 10th Annual Land O'Lakes Conference on Drug Metabolism/Applied Pharmacokinetics

August 9, 2007 - Thursday
President & CEO Patrick Lu Speaks at IBC's 12th Annual World Congress

August 6, 2007- Monday
Sirnaomics News: Company Submits Applications for Two Government Grants to Enhance Its R&D Work

August 2, 2007 - Friday
Sirnaomics News: County Officer Visits Sirnaomics to Present Certification

July 31, 2007 - Tuesday
Harry Yang on Board as Company's Co-founder and Senior Vice President - Strategic Planning & Asia Operation

July 2, 2007 - Monday
Sirnaomics News: Company Moves into New Facilities with Its Funding Partner GRL, Inc.

June 11, 2007 - Monday
George Ji On Board Sirnaomics as Company's Co-founder and Vice President - Corporate Development